Difference between revisions of "Pancreatic cancer - historical"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "4 PubMed" to "4/ PubMed")
m (Text replacement - "'''contains dosing details in abstract'''" to "'''dosing details in abstract have been reviewed by our editors'''")
 
(10 intermediate revisions by 2 users not shown)
Line 1: Line 1:
−
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? See the [[Pancreatic_cancer|main pancreatic cancer page]] for current regimens.
+
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the [[Pancreatic_cancer|main pancreatic cancer page]] for current regimens.
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
|-
 
|-
Line 9: Line 9:
 
==FLEC {{#subobject:a6c123|Regimen=1}}==
 
==FLEC {{#subobject:a6c123|Regimen=1}}==
 
FLEC: '''<u>F</u>'''luorouracil, '''<u>L</u>'''eucovorin (Folinic acid), '''<u>E</u>'''pirubicin, '''<u>C</u>'''arboplatin
 
FLEC: '''<u>F</u>'''luorouracil, '''<u>L</u>'''eucovorin (Folinic acid), '''<u>E</u>'''pirubicin, '''<u>C</u>'''arboplatin
−
<div class="toccolours" style="background-color:#eeeeee">
+
<div class="toccolours" style="background-color:#ee6b6e">
 
===Regimen {{#subobject:ac72e0|Variant=1}}===
 
===Regimen {{#subobject:ac72e0|Variant=1}}===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
Line 22: Line 22:
 
| style="background-color:#1a9851" |Phase 3 (E-esc)
 
| style="background-color:#1a9851" |Phase 3 (E-esc)
 
|[[Pancreatic_cancer#Gemcitabine_monotherapy_2|Gemcitabine]]
 
|[[Pancreatic_cancer#Gemcitabine_monotherapy_2|Gemcitabine]]
−
| style="background-color:#91cf60" |Seems to have superior OS
+
| style="background-color:#91cf60" |Seems to have superior OS (primary endpoint)
 
|-
 
|-
 
|}
 
|}
 
<div class="toccolours" style="background-color:#b3e2cd">
 
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
−
*[[Fluorouracil (5-FU)]]
+
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup> IA bolus once on day 1
−
*[[Folinic acid (Leucovorin)]]
+
*[[Leucovorin (Folinic acid)]] 100 mg/m<sup>2</sup> IA bolus once on day 1
−
*[[Epirubicin (Ellence)]]
+
*[[Epirubicin (Ellence)]] 60 mg/m<sup>2</sup> IA bolus once on day 1
−
*[[Carboplatin (Paraplatin)]]
+
*[[Carboplatin (Paraplatin)]] 300 mg/m<sup>2</sup> IA bolus once on day 1
 +
'''21-day cycle for 3 cycles'''
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
#Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, Comella G, Ceravolo C, Miserocchi L, Mambrini A, Del Freo A, Zamagni D, Rabbi C, Marangolo M. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. J Chemother. 2004 Dec;16(6):589-94. [https://doi.org/10.1179/joc.2004.16.6.589 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15700852/ PubMed]
+
#Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, Comella G, Ceravolo C, Miserocchi L, Mambrini A, Del Freo A, Zamagni D, Rabbi C, Marangolo M. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. J Chemother. 2004 Dec;16(6):589-94. [https://doi.org/10.1179/joc.2004.16.6.589 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/15700852/ PubMed]
 +
 
 
=Metastatic disease, first-line=
 
=Metastatic disease, first-line=
 
==PEFG {{#subobject:f0e123|Regimen=1}}==
 
==PEFG {{#subobject:f0e123|Regimen=1}}==
 
PEFG: '''<u>P</u>'''latinol (Cisplatin), '''<u>E</u>'''pirubicin, '''<u>F</u>'''luorouracil, '''<u>G</u>'''emcitabine
 
PEFG: '''<u>P</u>'''latinol (Cisplatin), '''<u>E</u>'''pirubicin, '''<u>F</u>'''luorouracil, '''<u>G</u>'''emcitabine
−
<div class="toccolours" style="background-color:#eeeeee">
+
<div class="toccolours" style="background-color:#ee6b6e">
 
===Regimen {{#subobject:5d6ee0|Variant=1}}===
 
===Regimen {{#subobject:5d6ee0|Variant=1}}===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
Line 49: Line 51:
 
|2000-2003
 
|2000-2003
 
| style="background-color:#1a9851" |Phase 3 (E-esc)
 
| style="background-color:#1a9851" |Phase 3 (E-esc)
−
|[[Pancreatic_cancer#Gemcitabine_monotherapy_3|Gemcitabine]]
+
|[[Pancreatic_cancer#Gemcitabine_monotherapy_5|Gemcitabine]]
−
| style="background-color:#91cf60" |Seems to have superior PFS
+
| style="background-color:#1a9850" |Superior PFS4 (primary endpoint)<br>PFS4: 60% vs 28%<br>(HR 0.46, 95% CI 0.26-0.79)
 
|-
 
|-
 
|}
 
|}
Line 62: Line 64:
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
#Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol. 2005 Jun;6(6):369-76. [https://doi.org/10.1016/S1470-2045(05)70175-3 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/15925814/ PubMed]
+
#Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol. 2005 Jun;6(6):369-76. [https://doi.org/10.1016/S1470-2045(05)70175-3 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/15925814/ PubMed]
 +
 
 
=Metastatic disease, all lines of therapy=
 
=Metastatic disease, all lines of therapy=
 
==SMF {{#subobject:f7dcb5|Regimen=1}}==
 
==SMF {{#subobject:f7dcb5|Regimen=1}}==
 
SMF: '''<u>S</u>'''treptozotocin, '''<u>M</u>'''itomycin, 5-'''<u>F</u>'''luorouracil
 
SMF: '''<u>S</u>'''treptozotocin, '''<u>M</u>'''itomycin, 5-'''<u>F</u>'''luorouracil
−
<div class="toccolours" style="background-color:#eeeeee">
+
<div class="toccolours" style="background-color:#ee6b6e">
 
===Regimen {{#subobject:251b74|Variant=1}}===
 
===Regimen {{#subobject:251b74|Variant=1}}===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
Line 78: Line 81:
 
|1987-1989
 
|1987-1989
 
| style="background-color:#1a9851" |Phase 3 (C)
 
| style="background-color:#1a9851" |Phase 3 (C)
−
|[[#CAC_99|CAC]]
+
|[[#CAC_999|CAC]]
 
| style="background-color:#1a9850" |Superior OS
 
| style="background-color:#1a9850" |Superior OS
 
|-
 
|-
Line 84: Line 87:
 
<div class="toccolours" style="background-color:#b3e2cd">
 
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
−
*[[Streptozocin (Zanosar)]]
+
*[[Streptozocin (Zanosar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1, 8, 29, 36
−
*[[Mitomycin (Mutamycin)]]
+
*[[Mitomycin (Mutamycin)]] 10 mg/m<sup>2</sup> IV once on day 1
−
*[[Fluorouracil (5-FU)]]
+
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once per day on days 1, 8, 29, 36
 +
'''8-week cycles'''
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
#Kelsen D, Hudis C, Niedzwiecki D, Dougherty J, Casper E, Botet J, Vinciguerra V, Rosenbluth R. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer. 1991 Sep 1;68(5):965-9. [https://doi.org/10.1002/1097-0142(19910901)68:5%3C965::aid-cncr2820680509%3E3.0.co;2-2 link to original article] [https://pubmed.ncbi.nlm.nih.gov/1833042/ PubMed]
+
#Kelsen D, Hudis C, Niedzwiecki D, Dougherty J, Casper E, Botet J, Vinciguerra V, Rosenbluth R. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer. 1991 Sep 1;68(5):965-9. [https://doi.org/10.1002/1097-0142(19910901)68:5%3C965::aid-cncr2820680509%3E3.0.co;2-2 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/1833042/ PubMed]
 
[[Category:Pancreatic cancer regimens]]
 
[[Category:Pancreatic cancer regimens]]
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
 
[[Category:Gastrointestinal cancers]]
 
[[Category:Gastrointestinal cancers]]
 
[[Category:Historical regimens]]
 
[[Category:Historical regimens]]

Latest revision as of 23:34, 15 July 2024

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the main pancreatic cancer page for current regimens.

3 regimens on this page
3 variants on this page


Induction therapy for locally advanced disease, unresectable

FLEC

FLEC: Fluorouracil, Leucovorin (Folinic acid), Epirubicin, Carboplatin

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Cantore et al. 2004 1997-2001 Phase 3 (E-esc) Gemcitabine Seems to have superior OS (primary endpoint)

Chemotherapy

21-day cycle for 3 cycles

References

  1. Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, Comella G, Ceravolo C, Miserocchi L, Mambrini A, Del Freo A, Zamagni D, Rabbi C, Marangolo M. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. J Chemother. 2004 Dec;16(6):589-94. link to original article dosing details in abstract have been reviewed by our editors PubMed

Metastatic disease, first-line

PEFG

PEFG: Platinol (Cisplatin), Epirubicin, Fluorouracil, Gemcitabine

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Reni et al. 2005 2000-2003 Phase 3 (E-esc) Gemcitabine Superior PFS4 (primary endpoint)
PFS4: 60% vs 28%
(HR 0.46, 95% CI 0.26-0.79)

Chemotherapy

28-day cycles

References

  1. Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol. 2005 Jun;6(6):369-76. link to original article dosing details in abstract have been reviewed by our editors PubMed

Metastatic disease, all lines of therapy

SMF

SMF: Streptozotocin, Mitomycin, 5-Fluorouracil

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Kelsen et al. 1991 1987-1989 Phase 3 (C) CAC Superior OS

Chemotherapy

8-week cycles

References

  1. Kelsen D, Hudis C, Niedzwiecki D, Dougherty J, Casper E, Botet J, Vinciguerra V, Rosenbluth R. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer. 1991 Sep 1;68(5):965-9. link to original article dosing details in manuscript have been reviewed by our editors PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Pancreatic_cancer_-_historical&oldid=89713"